A disappointing phase 3 study last year prompted Novo Nordisk to drop the blood pressure candidate ocedurenone.
发布者：BY CHRISTOPHER DUE KARLSSON，转转请注明出处：https://robotalks.cn/novo-nordisk-seeks-million-dollar-damages-following-failed-acquisition/
Novo Nordisk seeks million-dollar damages following failed acquisition
赞 (0)
关于作者
Trump Proposes New Ship Fees to Challenge China’s Maritime Might
上一篇
22 2 月, 2025 5:55 下午
Pharma leaders to meet Trump in push to tweak drug policies
下一篇
22 2 月, 2025 6:18 下午
相关推荐
-
Helping AI agents search to get the best results out of large language models
Whether you’re a researcher conceptualizing research study concepts or a chief executive officer wishing to automate a job in personnels or money, you’ll discover that …
-
Quality – Standing out from the Crowd
In the most recent installation of the High quality Issues collection, our Q&A with Martin Kjærbo, UR’s VP of Workflow and Supply Chain discusses UR’s high quality…
-
Partnering With Artists for the AI Action Summit in Paris
Takeaways – – – • For this year’s AI Activity Top occasions in Paris, we partnered with musicians and organizations to display the possibility of AI as a co…
-
CuFe to divest JWD mine iron ore rights in WA to Newcam
CuFe has actually authorized a binding term sheet for the sale of its iron ore civil liberties at the JWD mine in Western Australia to Newcam for A$ 12m ($ 8.13 m) in money. The bl…
-
As the rescued astronauts return, space law is still in orbit over who’s responsible when missions go wrong
Currently back in the world many thanks to Area X’s Dragon pill, astronauts Suni Williams and Butch Wilmore will certainly be taking a breath fresh air once more after a grue…
